Empreses emergents
2021
ENDOLIPID THERAPEUTICS SLPèptids que imiten la funció de l'SHBG: innovació per reduir l'acumulació de greix ectòpic
Adreça
Passeig de la Vall d'Hebron 119-129, 08035 Barcelona, Espanya
Dades financeres
Propietat CERCA
Barcelona, Spain
2002
Vall d’Hebron Institut de Recerca (VHIR)
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
Reduce ectopic fat
Mimicking SHBG: A new mechanism of action to reduce ectopic fat, with strong science fundament and interesting applications
Cellulite and NASH
Peptides EDL3D and EDL6D for celluite and NASH applications
2-Speed business model
Business model with short- and long-term assets that allow an early return in 2023
Mimicking SHBG: A new mechanism of action to reduce ectopic fat, with strong science fundament and interesting applications
Cellulite and NASH
Peptides EDL3D and EDL6D for celluite and NASH applications
2-Speed business model
Business model with short- and long-term assets that allow an early return in 2023
Descripció del producte
The ENDOLIPID Technology. SHBG-mimic Peptides
Peptides mimicking SHBG are useful to treat fatty liver diseases and reduce cellulite. Therapeutic and dermocosmetic applications.
Two peptides, EDL3D (Cellulite) is ready for co-development and EDL6D (NASH) is in PoC.
EDL3D – Cellulite.
New MoA with strong science fundaments
Strong lipolytic effect
Favourable safety profile
Peptide ready for co-development and license-out
ADL6D Nash
EDL6D – NASH.
New MoA with strong science fundaments
Outstanding efficacy hitting the 4 causes of the disease
Favourable safety profile
Peptide in in vivo validation in mice (PoC)
Peptides mimicking SHBG are useful to treat fatty liver diseases and reduce cellulite. Therapeutic and dermocosmetic applications.
Two peptides, EDL3D (Cellulite) is ready for co-development and EDL6D (NASH) is in PoC.
EDL3D – Cellulite.
New MoA with strong science fundaments
Strong lipolytic effect
Favourable safety profile
Peptide ready for co-development and license-out
ADL6D Nash
EDL6D – NASH.
New MoA with strong science fundaments
Outstanding efficacy hitting the 4 causes of the disease
Favourable safety profile
Peptide in in vivo validation in mice (PoC)